Despite the fact that less than 20% of the proteome has enzymatic activity, most drug development efforts have so far focused on identifying enzymatic inhibitors. However, targeting a cell’s proteasomal machinery is now considered an effective area of research. As…
19th November 2018, Pomezia, Italy – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
IRBM researchers, led by Dr. Edith Monteagudo, have published a novel method to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. Click on the link below to visit the article’s page on ScienceDirect. A liquid chromatography high-resolution…
